JAJonathan D. Ashwell

Jonathan D. Ashwell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan D. Ashwell has a total of 133 co-authors. Here are the top co-authors by number of shared publications:

  • Ivana Munitic

    Laboratory for Molecular Immunology, Faculty of Biotechnology and Drug Development, University of Rijeka, R. Matejčić 2, 51000 Rijeka, Croatia

    9 shared publications
  • Maria Letizia Giardino Torchia

    Department of Oncology Research, MedImmune, LLC, Gaithersburg, MD 20878

    9 shared publications
  • Matthew D. Taves

    Department of Psychology, University of British Columbia, Vancouver, British Columbia, Canada

    8 shared publications
  • Dietrich B. Conze

    Laboratory of Immune Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

    5 shared publications
  • Paul R. Mittelstadt

    Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA

    5 shared publications
  • Chuan-Jin Wu

    Laboratory of Immune Cell Biology, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA

    4 shared publications

Latest Publications

  • Open Access

    TNFR1 signaling promotes pancreatic tumor growth by limiting dendritic cell number and function

    by Muhammad S. Alam, Matthias M. Gaida, Hagen R. Witzel, Shizuka Otsuka, Aamna Abbasi, Theresa Guerin, Abdalla Abdelmaksoud, Nathan Wong, Margaret C. Cam, Serguei Kozlov, et al.


  • Open Access

    Calcineurin is an adaptor required for assembly of the TCR signaling complex

    by Shizuka Otsuka, Debjani Dutta, Chuan-Jin Wu, Muhammad S. Alam, Jonathan D. Ashwell


  • Open Access

    Centrosome amplification and aneuploidy driven by the HIV-1-induced Vpr•VprBP•Plk4 complex in CD4+ T cells

    by Jung-Eun Park, Tae-Sung Kim, Yan Zeng, Melissa Mikolaj, Jong Il Ahn, Muhammad S. Alam, Christina M. Monnie, Victoria Shi, Ming Zhou, Tae-Wook Chun, et al.

    HIV-1 infection elevates the risk of developing various cancers, including T-cell lymphoma. Whether HIV-1-encoded proteins directly contribute to oncogenesis remains unknown. We observe that approximately 1–5% of CD4+ T cells from the blood of people living with HIV-1 exhibit over-duplicated centrioles, suggesting that centrosome amplification underlies the development of HIV-1-associated cancers by driving aneuploidy. Through affinity purification, biochemical, and cellular analyses, we discover that Vpr, an accessory protein of HIV-1, hijacks the centriole duplication machinery and induces centrosome amplification and aneuploidy. Mechanistically, Vpr forms a cooperative ternary complex with an E3 ligase subunit, VprBP, and polo-like kinase 4 (Plk4). Unexpectedly, however, the complex enhances Plk4’s functionality by promoting its relocalization to the procentriole assembly and induces centrosome amplification. Loss of either Vpr’s C-terminal 17 residues or VprBP acidic region, the two elements required for binding to Plk4 cryptic polo-box, abrogates Vpr’s capacity to induce these events. Furthermore, HIV-1 WT, but not its Vpr mutant, induces multiple centrosomes and aneuploidy in human primary CD4+ T cells. We propose that the Vpr•VprBP•Plk4 complex serves as a molecular link that connects HIV-1 infection to oncogenesis and that inhibiting the Vpr C-terminal motif may reduce the occurrence of HIV-1-associated cancers.


  • Open Access

    Biosynthesis of glucocorticoids in tumors. Reply.

    by Matthew D. Taves, Shizuka Otsuka, Jonathan D. Ashwell


  • Open Access

    Tumors produce glucocorticoids by metabolite recycling, not synthesis, and activate Tregs to promote growth

    by Matthew D. Taves, Shizuka Otsuka, Michaela A. Taylor, Kaitlynn M. Donahue, Thomas J. Meyer, Margaret C. Cam, Jonathan D. Ashwell

    Glucocorticoids are steroid hormones with potent immunosuppressive properties. Their primary source is the adrenals, where they are generated via de novo synthesis from cholesterol. In addition, many tissues have a recycling pathway in which glucocorticoids are regenerated from inactive metabolites by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1, encoded by Hsd11b1). Here, we find that multiple tumor types express Hsd11b1 and produce active glucocorticoids. Genetic ablation of Hsd11b1 in such cells had no effect on in vitro growth, but reduced in vivo tumor progression, which corresponded with increased frequencies of CD8+ tumor-infiltrating lymphocytes (TILs) expressing activation markers and producing effector cytokines. Tumor-derived glucocorticoids were found to promote signatures of Treg activation and suppress signatures of conventional T cell activation in tumor-infiltrating Tregs. Indeed, CD8+ T cell activation was restored and tumor growth reduced in mice with Treg-specific glucocorticoid receptor deficiency. Importantly, pharmacologic inhibition of 11β-HSD1 reduced tumor growth to the same degree as gene knockout and rendered immunotherapy-resistant tumors susceptible to PD-1 blockade. Given that HSD11B1 expression is upregulated in many human tumors and that inhibition of 11β-HSD1 is well tolerated in clinical studies, these data suggest that targeting 11β-HSD1 may be a beneficial adjunct in cancer therapy.


  • Open Access

    Centrosome amplification and aneuploidy driven by the HIV-1-induced Vpr•VprBP•Plk4 complex in CD4+ T cells

    by Kyung Lee, Jung-Eun Park, Tae-Sung Kim, Yan Zeng, Christina Monnie, Muhammad Alam, Ming Zhou, Melissa Mikolaj, Frank Maldarelli, Kedar Narayan, et al.

    HIV-1 infection elevates the risk of developing various cancers, including T-cell lymphoma. Whether HIV-1-encoded proteins directly contribute to oncogenesis remains unknown. We observed that approximately 1–5% of CD4+ T cells from the blood of people living with HIV-1 exhibit over-duplicated centrioles, suggesting that centrosome amplification underlies the development of HIV-1-associated cancers by driving aneuploidy. Through affinity purification, biochemical, and cell biology analyses, we discovered that Vpr, an accessory protein of HIV-1, hijacks the centriole duplication machinery and induces centrosome amplification and aneuploidy. Mechanistically, Vpr formed a cooperative ternary complex with an E3 ligase subunit, VprBP, and polo-like kinase 4 (Plk4). Unexpectedly, however, the complex enhanced Plk4’s functionality by promoting its relocalization to the procentriole assembly and induced centrosome amplification. Loss of either Vpr’s C-terminal 17 residues or VprBP acidic region, the two elements required for binding to Plk4 cryptic polo-box, abrogated Vpr’s capacity to induce all these events. Furthermore, HIV-1 WT, but not its Vpr mutant, induced multiple centrosomes and aneuploidy in primary CD4+ T cells. We propose that the Vpr•VprBP•Plk4 complex serves as a molecular link that connects HIV-1 infection to oncogenesis and that inhibiting the Vpr C-terminal motif may reduce the occurrence of HIV-1-associated cancers.

  • Aire drives steroid hormone biosynthesis by medullary thymic epithelial cells

    by Matthew D. Taves, Kaitlynn M. Donahue, Jing Bian, Margaret C. Cam, Jonathan D. Ashwell

    Thymic epithelial cells (TECs) produce glucocorticoids, which antagonize negative selection of autoreactive thymocytes and promote a competent T cell antigen–specific repertoire. To characterize their source, we generated a knock-in reporter mouse in which endogenous Cyp11b1, the final enzyme in de novo production of active glucocorticoids, was fluorescently tagged with mScarlet. Here, we find that Cyp11b1 is expressed in medullary TECs (mTECs) but not cortical TECs or other cells in the thymus. A distinct characteristic of mTECs is the presence of Aire, a transcription factor that drives expression of tissue-restricted antigens (TRAs) important for establishing immune tolerance. Cyp11b1 expression was highest in Aire + mTECs, lower in post-Aire mTECs, and absent in mTECs of Aire -deficient mice. Transcriptomic analyses found that multiple enzymatic biosynthetic pathways are expressed specifically in mTECs and are also Aire dependent. In particular, we found that the thymus expresses messenger RNA for enzymes that catalyze production of many bioactive steroids and that glucocorticoids and sex steroids were secreted by cultured thymi. Expression of the transcripts for these genes and production of their final steroid products were markedly reduced in the absence of Aire. Thus, in addition to its well-established role in inducing TRAs that promote negative selection, Aire has an additional and contrary function of inducing glucocorticoids that antagonize negative selection, which together may expand and enhance the TCR repertoire. Furthermore, because Aire drives expression of multiple enzymes responsible for production of other non–gene-encoded bioactive molecules, it might have yet other roles in thymus development and function.


  • Open Access

    Effects of sex steroids on thymic epithelium and thymocyte development

    by Matthew D. Taves, Jonathan D. Ashwell

    Sex steroid hormones have major effects on the thymus. Age-related increases in androgens and estrogens and pregnancy-induced increases in progestins all cause dramatic thymic atrophy. Atrophy can also be induced by treatment with exogenous sex steroids and reversed by ablation of endogenous sex steroids. Although these observations are frequently touted as evidence of steroid lymphotoxicity, they are often driven by steroid signaling in thymic epithelial cells (TEC), which are highly steroid responsive. Here, we outline the effects of sex steroids on the thymus and T cell development. We focus on studies that have examined steroid signalingin vivo, aiming to emphasize the actions of endogenous steroids which,viaTEC, have remarkable programming effects on the TCR repertoire. Due to the dramatic effects of steroids on TEC, especially thymic involution, the direct effects of sex steroid signaling in thymocytes are less well understood. We outline studies that could be important in addressing these possibilities, and highlight suggestive findings of sex steroid generation within the thymus itself.


  • TNF plays a crucial role in inflammation by signaling via T cell TNFR2

    by Muhammad S. Alam, Shizuka Otsuka, Nathan Wong, Aamna Abbasi, Matthias M. Gaida, Yu Fan, Daoud Meerzaman, Jonathan D. Ashwell

    TNF, produced largely by T and innate immune cells, is potently proinflammatory, as are cytokines such as IFN-γ and IL-17 produced by Th1 and Th17 cells, respectively. Here, we asked if TNF is upstream of Th skewing toward inflammatory phenotypes. Exposure of mouse CD4+ T cells to TNF and TGF-β generated Th17 cells that express low levels of IL-17 (ROR-γt+IL-17lo) and high levels of inflammatory markers independently of IL-6 and STAT3. This was mediated by the nondeath TNF receptor TNFR2, which also contributed to the generation of inflammatory Th1 cells. Single-cell RNA sequencing of central nervous system–infiltrating CD4+ T cells in mouse experimental autoimmune encephalomyelitis (EAE) found an inflammatory gene expression profile similar to cerebrospinal fluid–infiltrating CD4+ T cells from patients with multiple sclerosis. Notably, TNFR2-deficient CD4+ T cells produced fewer inflammatory mediators and were less pathogenic in EAE and colitis. IL-1β, a Th17-skewing cytokine, induced TNF and proinflammatory granulocyte-macrophage colony-stimulating factor (GM-CSF) in T cells, which was inhibited by disruption of TNFR2 signaling, demonstrating IL-1β can function indirectly via the production of TNF. Thus, TNF is not just an effector but also an initiator of inflammatory Th differentiation. Significance Inflammatory diseases are mediated by products such as TNF and IL-17 produced by T helper (Th) cell subsets. Here, we identify a direct role for TNF in the production of pathogenic T cells, particularly cells that produce IL-17 (Th17) and interferon-γ (Th1). We found that TNF shapes the inflammatory response by signaling via its relatively unstudied “minor” receptor, TNFR2, skewing T cells to become inflammatory Th17 cells and enhancing inflammatory cytokine production by Th1 cells. Preventing TNFR2 signaling resulted in reduced disease in mouse models of multiple sclerosis and colitis. This work integrates the importance of TNF with Th17/Th1 cell pathogenicity and may explain the paradox that IL-17–dependent diseases, such as psoriasis and ankylosing spondylitis, respond to anti-TNF monotherapy.